How Ivermectin and Fenbendazole Are Thought to Act on Cancer Cells

Source note: this article draws on a recorded interview with an oncologist who runs a cancer coaching practice built around repurposed antiparasitic drugs. The claims below are his clinical interpretation of the preclinical literature, not an independent systematic review — the evidence-quality caveats are called out throughout.

A pattern medicine has seen before

Aspirin began as an extract of willow bark, used for treating fevers, before anyone realized it also reduces platelet viscosity and helps prevent blood clotting. A drug originally introduced for treating angina was later found, by surprise, to treat a completely different condition. Repurposing an existing drug for a new use is not a new idea in medicine — it has happened before.

The oncologist interviewed for this piece says his own interest in repurposed drugs began when he started writing on Substack and set out to do a deep dive into early COVID-19 treatments — ivermectin and hydroxychloroquine specifically — to work out for himself whether the science supported them. Reading through that literature, he kept running into something unrelated to viruses at all: a large body of published research on ivermectin and cancer.

The scale of the preclinical record

A PubMed search turns up more than 300 peer-reviewed papers on ivermectin and cancer. That is not one lab's pet project — it is a substantial, distributed body of work spanning blood cancers and solid tumors, built up over years by researchers studying cancer cell lines and animal models. The mechanisms described are varied enough that ivermectin has been characterized as a broad-spectrum anti-cancer agent rather than a drug that works through a single pathway.

The benzimidazole family — fenbendazole and its FDA-approved near-twin, mebendazole, which differ by a single atom — carries a similar weight of preclinical literature, plus something ivermectin does not yet have: roughly a dozen active clinical trials in humans, mostly looking at mebendazole in pediatric and adult cancers, because its FDA-approved status made oncologists more willing to study it formally.

What neither drug has, for cancer, is a completed randomized controlled trial in humans. There are case reports. There is a small case series of three leukemia patients, two of whom reportedly achieved some form of remission on ivermectin. There is nothing at the scale that would let a regulator or a guideline committee say, with confidence, that these drugs treat cancer in people. The gap between the preclinical enthusiasm and the clinical evidence is the central tension in this story, and it traces back to an unglamorous fact: both drugs have been off-patent since the 1990s, so no pharmaceutical company stands to recoup the cost of a Phase III trial. Research funding tends to follow patents, not patients.

Ivermectin: a dozen mechanisms, one antiparasitic

What makes ivermectin interesting to cancer researchers is that its proposed anti-cancer activity does not run through one mechanism — it runs through several, each independently documented in preclinical work:

• Targeting cancer stem cells. Standard chemotherapy is built to kill rapidly dividing cells, which is why it shrinks tumors quickly. But a subpopulation of slow-dividing cancer stem cells often survives chemotherapy untouched — and these are the cells implicated in recurrence and metastasis years later. This is part of why oncologists describe chemotherapy for cancers like stage IV pancreatic or ovarian cancer as palliative rather than curative: it can shrink the visible tumor without touching the cells most likely to cause a comeback. Ivermectin is described in preclinical work as acting on these cancer stem cells specifically.
• Reversing multi-drug resistance. Cancer cells can develop pumps that eject chemotherapy drugs before they take effect, which is why oncologists often have to switch a patient to a new chemo agent after resistance develops. Ivermectin is reported to interfere with this resistance mechanism, potentially re-sensitizing resistant cells to chemotherapy that had stopped working.
• Radiosensitization. Separately, ivermectin is described as sensitizing cancer cells to radiation-induced cell death, which would allow a given dose of radiation therapy to do more damage to the tumor.
• Anti-angiogenesis. Tumors need to grow new blood vessels to keep expanding and to metastasize; ivermectin is reported to inhibit this process.
• Matrix metalloproteinase inhibition. These enzymes let cancer cells detach from the primary tumor and travel through the bloodstream to seed new sites. Blocking them is described as a way of inhibiting metastasis directly.
• Pro-apoptotic signaling. Several of these pathways converge on programmed cell death — changing the expression of specific proteins in a way that pushes the cancer cell toward apoptosis rather than continued proliferation.

One detail researchers flag as particularly notable: in laboratory studies, ivermectin has been shown to identify and act on cancer cells — lymphoma cells, specifically, in one line of research — while leaving normal cells comparatively unaffected. That kind of selectivity is what pharmacologists sometimes call a "magic bullet" quality, though it is worth remembering this selectivity has been observed in vitro and in animal models, not established as a guaranteed property in every person's cancer.

Fenbendazole and mebendazole: starving the cell, disrupting its skeleton

The mechanism the interviewed physician highlights for this family: fenbendazole and mebendazole block glucose transporters specifically on cancer cells, starving them of glucose as a fuel source without producing the same effect on normal cells. Asked why a drug would be able to target the glucose transporter on a cancer cell but not a normal one, he pointed to a biochemical difference between the two — the same kind of cancer-versus-normal-cell selectivity he describes for ivermectin.

Mebendazole and fenbendazole are not interchangeable in practice, according to the preclinical record:

• Blood-brain barrier penetration. Mebendazole crosses the blood-brain barrier more effectively than fenbendazole, which is why it is described as the preferred agent for brain tumors and brain metastases.
• Solubility problems. South Korean researchers studying fenbendazole in ovarian cancer found strong activity in vitro that did not translate well into mouse models — a solubility problem that is now driving research into nanoparticle delivery formulations to get the drug to the tumor more efficiently. Mebendazole does not appear to share this limitation to the same degree, which is part of why it is favored for ovarian cancer specifically, along with squamous cell carcinomas, breast cancer, and sarcomas, where more supportive preclinical data exists.

Why combine them

The preclinical literature also documents synergy: ivermectin combined with a benzimidazole, and either combined with standard chemotherapy or radiation, produces more cancer cell killing in lab studies than any single agent alone. Mechanistically this tracks — if one drug is reversing drug resistance and sensitizing cells to chemotherapy, while another is cutting off the cell's fuel supply and disrupting its internal scaffolding, the combined effect on a vulnerable cell is plausibly larger than the sum of the parts. This is consistent with — though distinct from — the precedent of low-dose naltrexone being used as a chemotherapy sensitizer in other contexts.

Where the science stands

None of these mechanisms are speculative in the sense of being invented for this purpose — they describe known biochemical pathways, studied with standard bench techniques, published and in many cases replicated across dozens of independent papers. That is a meaningfully different category from an unproven theory with no mechanism at all, and it is why researchers in this space describe the case for a plausible biological effect as strong.

But a plausible mechanism is not the same thing as clinical proof. Every mechanism described here comes from cell lines, animal models, or a handful of human case reports — not from the randomized controlled trials that would be needed to establish how reliably, and in which cancers, these effects hold up in real patients at real doses. That gap is the subject of the next two pieces in this series: what doses are actually being used, and what happened to the patients who used them.